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Abstract: The aryl hydrocarbon receptor (AhR) is known for mediating the toxicity of environmental
pollutants such as dioxins and numerous dioxin-like compounds, and is associated with the promotion
of various malignancies, including lymphoma. The aryl hydrocarbon receptor repressor (AhRR),
a ligand-independent, transcriptionally inactive AhR-like protein is known to repress AhR signaling
through its ability to compete with the AhR for dimerization with the AhR nuclear translocator
(ARNT). While AhRR effectively blocks AhR signaling, several aspects of the mechanism of AhRR’s
functions are poorly understood, including suppression of inflammatory responses and its putative
role as a tumor suppressor. In a transgenic mouse that overexpresses AhRR (AhRR Tg) we discovered
that these mice suppress 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)- and inflammation-induced
tumor growth after subcutaneous challenge of EL4 lymphoma cells. Using mouse embryonic
fibroblasts (MEF) we found that AhRR overexpression suppresses the AhR-mediated anti-apoptotic
response. The AhRR-mediated inhibition of apoptotic resistance was associated with a suppressed
expression of interleukin (IL)-1β and cyclooxygenase (COX)-2, which was dependent on activation
of protein kinase A (PKA) and the CAAT-enhancer-binding protein beta (C/EBPβ). These results
provide mechanistic insights into the role of the AhRR to suppress inflammation and highlight the
AhRR as a potential therapeutic target to suppress tumor growth.
Keywords: AhR; AhRR; carcinogenicity; C/EBPβ; cyclooxygenase 2; inflammation; interleukin 1;
lymphoma; TCDD
1. Introduction
Human exposure to dioxins and dioxin-like compounds has been associated with a range of
toxic effects including human carcinogenicity at multiple sites in occupational settings. Numerous
dioxin-like compounds (polybrominated dibenzo-p-dioxins, dibenzofurans, biphenyls, and polycyclic
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aromatic hydrocarbons) can be abundant in the environment and have the potential to contribute to
our daily background exposure. It has been previously shown that they mediate their toxicity through
activation of the aryl hydrocarbon receptor (AhR) [1]. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) as
the prototypical ligand of AhR acts as a potent tumor promoter in various animal models and may
cause tumors at multiple sites [2]. Exposure to dioxin and dioxin-like compounds has been shown to
be carcinogenic and especially associated with the development of non-Hodgkin lymphoma (NHL)
in mice [3,4] and in humans [5]. A recent meta-analysis demonstrated that the degree of external
exposure and the blood levels of TCDD are significantly associated with cancer incidence and mortality,
especially for NHL [6]. The AhR may also act as a critical receptor protein that mediates carcinogenesis
independent of exogenous ligands. AhR activation via endogenous ligands can represent a critical
event in human carcinogenesis and can result in the development of immune tolerance and increased
survival of cancer cells [7]. The mechanisms of TCDD-mediated toxicity and AhR-dependent tumor
promoting activity have been investigated in numerous studies with a focus on TCDD’s action as a
potent hepatic tumor promoter [2,8]. On the other hand, the mechanism of the AhR Repressor (AhRR)
acting as a tumor suppressor is poorly understood and has not been assessed in vivo.
AhRR, first described by Mimura et al. [9], has been identified as a bHLH-PAS protein but in
contrast to AhR, the AhRR does not express a functional ligand-binding and transactivation domain.
The AhRR has the ability to dimerize with the AhR nuclear translocator (ARNT) and act as a specific
inhibitor of AhR activity through the competition of AhRR with AhR to form heterodimers with ARNT
which hinders binding and transactivation of AhR/ARNT complexes via dioxin response elements
(DREs). However results of transfection experiments with ARNT and AhRR mutants suggest a more
complex mechanism in addition to the negative feedback mechanism through sequestration of ARNT
and inhibition of the AhR signaling pathway [10,11]. Recent studies also indicate that repression of
CYP1A1 activity is not always related to the expression level of AhRR [12]. These findings and a recent
study showing the structural analysis of AhRR/ARNT [13], support that AhRR may interact with other
transcription factors as proposed in the transrepression model by Evans et al. [14] and by our own
study using a transgenic mouse model overexpressing AhRR [15].
The ability of AhRR to regulate AhR’s signaling in major cellular processes, such as cell cycling,
inflammation, and apoptosis is complex and variable depending on the cellular and environmental
context. In vitro experiments with several different types of cancer cell lines showed that the AhRR may
act as a tumor suppressor gene [16,17]. Interestingly, a recent study identified numerous DNA binding
sites in gene promoter regions of tumor suppressor genes and genes involved in carcinogenesis uniquely
bound by AhRR [18]. In addition, epigenetic modifications of AhRR’s regulatory region have been
found in human studies which was associated with the exposure to cigarette smoke and development
of various types of cancer, e.g., [19]. Recently we established a transgenic mouse (AhRR Tg mice) that
overexpresses AhRR and discovered that these mice were protected from TCDD-induced lethality that
correlated with a reduction in inflammatory response and acute hepatotoxicity [15]. The current study
was designed to test the tumor suppressive function of AhRR and to better understand the regulatory
mechanisms of AhRR in inflammatory and cellular responses contributing to tumor promotion.
2. Results
2.1. Suppression of Tumor Growth in AhRR Tg Mice
To address the tumor-suppressive action of AhRR in vivo, we used a syngeneic murine tumor
model to assess changes in tumor susceptibility associated with inflammation. A common tumor
model to define host resistance against transplanted tumors in vivo is the xenograft model with EL4
lymphoma cells. The results indicate a significantly suppressed tumor growth of EL4 lymphoma in
AhRR Tg mice compared to wt B6 mice with or without TCDD treatment (Figure 1). Tumor growth
of EL4 lymphoma was enhanced in TCDD-treated wt mice compared to control wt mice (Figure 1A).
Furthermore, the TCDD-stimulated tumor growth of EL4 cells in wt mice was suppressed in the
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presence of the IL-1 receptor antagonist anakinra and NS-398, a selective COX-2 inhibitor (Figure 1B)
supporting our hypothesis that TCDD in part mediates its tumor promoting activity through the IL-1
receptor and COX-2.
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2.2. Resistance of AhRR Tg Mice to LPS
In order to test if AhRR suppresses inflammation-dependent tumor growth we treated mice with
LPS after subcutaneous injection of EL4 lymphoma cells. The results indicate an enhanced tumor
growth of EL4 lymphoma in LPS-treated wt mice compared to non-treated control wt mice (Figure 2A).
LPS-stimulated tumor growth of EL4 cells was significantly reduced in AhRR Tg mice compared to
wt mice. In order to further test the responsiveness of AhRR Tg mice toward LPS, we treated wt and
AhRR Tg mice with a lethal dose of 25 mg/kg of LPS (Figure 2B). The lethality was observed over
a period of 120 h after LPS injection. 50% of the wt mice died in the first 24 h after LPS treatment.
At 48 h 90% of wt mice died after LPS and all wt mice were dead after 72 h of treatment. In contrast,
none of the AhRR Tg mice died in the first 36 h of LPS treatment and 90% survived after 60 h of LPS
treatment. Only 20% of the AhRR Tg mice died after LPS at the end of the observation period at
120 h. Furthermore, we used LPS-sensitive bone marrow-derived macrophages (BMM) to test if AhRR
suppresses LPS-induced expression of IL-1β and COX-2 (Figure 2C). BMM derived from wt and AhRR
Tg mice were treated with 25 ng/mL LPS for 24 h and mRNA was analyzed by qPCR. The results
show a clear induction of COX-2 (610-fold) and IL-1β (633-fold) in BMM wt after LPS treatment. The
LPS-induced expression of both, IL-1β and COX-2 was more than 50% repressed in BMM AhRR Tg.
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Figure 2. Resistance of AhRR Tg mice to LPS. (A) Suppressed growth of LPS-induced tumor volume of
EL4 lymphoma cells in AhRR Tg mice. WT and AhRR Tg mice were treated i.p. with a single injection
of LPS (2.5 mg/kg bw; red lines). Tumor volume was measured over a period of 18 days. Means of
tumor volume are shown. a significantly higher than LPS-treated AhRR Tg and WT Ctrl mice (p < 0.01).
(B) 6-week-old male AhRR Tg mice and littermate WT mice (n = 8 for each group) were i.p. injected
with 25 mg/kg of LPS (red lines) or with the vehicle control PBS (black lines). Lethality was observed
over 120 h after LPS challenge. (C) AhRR suppresses LPS-induced expression of IL-1β and COX-2
in BMM. BMM derived from WT and AhRR Tg mice were treated with 100 ng/mL LPS for 24 h and
mRNA was analyzed by qPCR. b significantly lower than LPS-treated BMM WT (p < 0.005).
2.3. AhRR Suppresses TCDD-Induced Expression of Inflammatory Markers
To test the role of AhRR in inflammatory responses in vitro we used mouse embryonic fibroblasts
(MEF) from wt and AhRR Tg mice. MEF were treated with 1 nM TCDD for 24 h and RNA was extracted
to analyze the expression of IL-1β and COX-2. The mRNA expression of both, IL-1β and COX-2 was
induced in MEF wt by TCDD after 24 h of treatment (Figure 3A). The TCDD-induced expression
of IL-1β and COX-2 mRNA was significantly repressed in MEF overexpressing AhRR derived from
AhRR Tg mice compared to wt MEF. As reported earlier, the TCDD-mediated induction of COX-2
may involve the activation of PKA and DNA binding of C/EBPβ [20,21]. Therefore, we transiently
transfected MEF wt with an empty vector as control and dominant negative expression vectors PKAi
Cancers 2019, 11, 589 5 of 17
and A-C/EBP to inhibit PKA activation and DNA binding to C/EBP binding elements. The results
indicate that inhibition of PKA or C/EBP binding significantly inhibits TCDD-induced expression
of IL-1β as well as COX-2 (Figure 3B). MEF treated in Figure 3A were not transfected with “empty”
vector but levels of IL-1β and COX-2 are not significantly different from TCDD-treated and MEF
transfected with an empty vector in Figure 3B. Western blot analysis confirmed that the repressed
mRNA expression in AhRR Tg MEF affects the protein level of IL-1β and COX-2 (Figure 3C). TCDD
treatment increased the level of AhRR in AhRR Tg MEF but inhibited the increase of COX-2 and IL-1β.
The effect of TCDD on AhRR protein level was not detected in wt MEF.
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and AhR Tg mice were treated with 1 nM TCD for 24 h and mRNA expression f COX-2 and IL-1β
was analyzed by qPCR. a sign ficantly hig er than Ctrl; b significantly lower than wt, p < 0.05. (B)
TCDD-induced expression of COX-2 and IL-1β is PKA and C/EBP dependent. MEF wt were transfect d
with an empty vector as control and dominant negative expression vectors PKA-i or A-C/EBP. fter 16
h transfection MEF wt were treated with 1 nM TCDD for 24 h and mRNA expression was analyzed by
qPCR. a significantly higher than Ctrl; b si nificantly lower than wt, p < 0.05. (C) Repressed protein
level of IL-1β and COX-2 in AhRR Tg MEF determined by Western blot. MEF derived from wt or AhRR
Tg mice were treated for 24 h with 1 nM TCDD or vehicle (0.1% DMSO). ( ) densitometric evaluation
of band intensities of the western blot bands of MEF wt (open bars) and MEF AhRR Tg (shaded bars)
is presented. Results of three separate experiments are shown as mean values ± S.D. a significantly
different from control cells (p < 0.05).
2.4. Repressed DNA-Binding Activity of C/EBP in AhRR Tg MEF
The nuclear protein binding to the key responsive element C/EBP that is frequently found in
the promoters of pro-inflammatory genes and known to mediate expression of IL-1β and COX-2
was assessed using electrophoretic mobility shift assay (EMSA). Previously we found that enhanced
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expression of AhRR in mice repressed TCDD-induced up-regulation and nuclear accumulation of
C/EBPβ in vivo [15] and that the activity of C/EBPβ is important to mediate the induction of COX-2
by TCDD [20]. We confirmed our initial findings in MEF from wt and AhRR Tg mice which serve as
a suitable in vitro model to study the enhanced expression of AhRR. The results show a repressed
binding activity of C/EBP (Figure 4A) associated with suppressed protein levels of C/EBPβ (Figure 4B)
in the nuclei of TCDD-treated MEF overexpressing AhRR.
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Figure 4. AhRR represses the levels and activity of C/EBP. (A) Repressed DNA binding activity to a
C/EBP consensus element in AhRR Tg MEF compared to wt MEF. MEF from wt (lanes 1 and 2) and
AhRR Tg mice (lanes 3 and 4) were treated with 1 nM TCDD (lanes 2 and 4). After 4 h nuclear proteins
were extracted. For specificity a 200-fold molar excess of unlabeled probe was added as competitor
(lane 5). (B) Repressed protein level of C/EBPβ in AhRR Tg MEF. MEF from wt and AhRR Tg mice
were treated with 1 nM TCDD for 4h. Nuclear proteins were extracted and protein level of C/EBPβ
was determined by western blot. (C) densitometric evaluation of band intensities of the western blot
bands of MEF wt (open bars) and MEF AhRR Tg (shaded bars) is presented. Results of three separate
experiments are shown as mean values ± S.D. a significantly different from control cells (p < 0.05).
2.5. TCDD-Induced PKA Activity is Reduced in AhRR Tg MEF
Previously we have shown that TCDD activates PKA, which mediates the activation of C/EBPβ [21].
MEF were treated with 1 nM TCDD and PKA activity was determined after 2 h. TCDD increased
the basal PKA activity by 2.8-fold in MEF wt (Table 1). The TCDD-induced basal PKA activity was
significantly diminished in MEF AhRR Tg compared to MEF wt; however, treatment with TCDD
still increased PKA activity by 1.8-fold in MEF AhRR Tg compared to vehicle (0.1% DMSO) controls.
The total PKA activity was elevated 1.4-fold by TCDD in MEF wt and was significantly decreased
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in MEF AhRR Tg. The specific AhR antagonists MNF and CH223191 completely suppressed the
TCDD-induced PKA activity indicating that the AhR is required in this process. The total PKA activity
is cofactor dependent and measured after addition of cAMP. The basal activity, a measure of active
PKA at the time of harvest, is measured in the absence of exogenous cAMP. The basal PKA activity
was on average less than 10% of the total PKA activity.
Table 1. Effect of AhRR on TCDD-mediated PKA activity.
Treatment
PKA Activity (pmol/min/mg Protein)
MEF wt MEF AhRR Tg
basal total basal total
Control 110 ± 20 2644 ± 150 95 ± 14 2450 ± 32
TCDD 290 ± 38 a 3720 ± 240 a 170 ± 25 b 2865 ± 80 b
MNF+TCDD 145 ± 28 c 2830 ± 110 c 126 ± 40 c 2050 ± 90 c
CH223191+TCDD 123 ± 21 c 2540 ± 140 c 102 ± 20 c 1980 ± 110 c
MEF cells from wt and AhRR Tg mice were exposed to 1 nM TCDD in presence or absence of the AhR antagonists
MNF or CH223191. Total and basal PKA activities were measured after 2 h. The assay background has been
subtracted by using a PKA inhibitor peptide. Values are the mean ± S.D. of triplicates and are a significantly higher
than wt control (p < 0.005); b significantly lower than TCDD-treated wt cells (p < 0.005); c significantly lower than
TCDD-treated wt and AhRR Tg cells (p < 0.005).
2.5.1. PKA and C/EBPβ Mediate TCDD-Induced IL-1β Promoter Activity
IL-1β was identified as an AhR target gene [22] and as a prototypical gene suppressed by
AhRR [15,23]. Therefore, we selected the mouse IL-1β gene promoter to identify potential C/EBPβ
and AhR binding sites (canonical and non-canonical DREs), which could be affected by AhRR. Using
the TFSEARCH program we identified a consensus DRE site and a non-canonical AhR/RelB binding
element (RelBAhRE) for mouse IL-1β (Figure 5A). Three potential binding elements for C/EBPβ were
identified on the promoter region of the mouse IL-1β gene. A luciferase reporter construct has been
generated for mouse IL-1β, which is inducible by TCDD. The results show that TCDD-induced IL-1β
activity is significantly repressed in MEF derived from AhRR Tg and from RelB−/− mice (Figure 5B).
Co-transfection studies with a PKA inhibitor (PKA-i) and C/EBP dominant negative expression plasmid
(A-C/EBP) significantly blocked the TCDD-mediated activation of IL-1β promoter activity by about
50% (Figure 5C). The results indicate the importance of RelB and PKA/C/EBPβ in mediating the
transcriptional activation of the IL-1β gene by TCDD. Promoter analyses of COX-2 and IL-8 in our
previous studies confirm the important role of PKA, C/EBPβ, and RelB in TCDD-mediated gene
induction [20,21,24].
2.5.2. Enhanced Recruitment of AhR to a RelBAhRE Binding Site of the IL-1β Promoter
ChIP assays with antibodies against AhR and RelB proteins were analyzed by PCR using primer
pairs covering the specified RelBAhRE region of mouse IL-1β (Figure 6A). Genomic DNA and the
sonicated input DNA were separated by agarose gel electrophoresis and visualized by ethidium bromide
staining. ChIP assay samples from wt MEF and AhRR Tg MEF were analyzed as described [24]. The
results show that TCDD stimulates the recruitment of AhR to the RelBAhRE site of IL-1β 90 min. after
treatment (Figure 6A). The results indicate that AhRR inhibits the recruitment of TCDD-activated AhR
and RelB to the potential RelBAhRE site of the mouse IL-1β gene.
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Figure 5. TCDD-induced IL-1β promoter activity is RelB and PKA-C/EBPβ-dependent. (A) Potential
binding sites of the full-length promoter construct of the mouse IL-1β gene containing 2590 bp upstream
of the transcriptional start site (indicated by an arrow) cloned into a luciferase (luc) reporter vector.
Positions of one putative DRE consensus, one non-consensus DRE (RelBAhRE) and three recognition
sites for C/EBPβ are presented. (B) MEF from wt, AhRR Tg, and RelB−/− mice were transfected with a
luciferase reporter construct containing 2590 bp (IL-1β) of the mouse gene promoter region. (C) MEF
wt were cotransfected with an empty, PKA inhibitor (PKA-i) and C/EBP dominant negative expression
plasmid. 24 h after transfection, MEF were treated with 1 nM TCDD for 6 h. Relative luciferase activity
units are given as mean values of triplicates as a result of three independent experiments. a significantly
different from control cells (p < 0.05); b significantly lower than MEF wt or cells co-transfected with
empty vector (p < 0.05).
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Figure 6. TCDD stimulates the recruitment of AhR and RelB to the RelBAhRE region of the mouse
IL-1β promoter. (A) MEF derived from wt and AhRR Tg mice were treated with 1 nM TCDD for 90
min. ChIP assays were performed sing AhR- and RelB-specific antibodies followed by PCR analysis
with primer pairs covering the specified RelB E region of mouse IL-1β promoter. (B) Association of
hRR with ARNT and RelB. Co-IP of AhRR, ARNT, and RelB with RelB and AhRR antibody. MEF
fro wt and AhRR Tg mice were treated with 1 nM TCDD (T) or DMSO (C) for 90 min and cell lysates
were used for co-IP. Western blot analysis was performed to detect specific association of AhRR with
ARNT and RelB. Rabbit lgG as used as negative control.
2.5.3. Physical Association of AhRR, ARNT, and RelB
Here we tested the hypothesis that the AhRR in complex with ARNT interacts with RelB. The
AhRR can form heterodimers with ARNT to repress AhR-dependent transactivation [14]. Moreover, it
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was shown that ARNT interacts with RelB [25] resulting in inhibition of RelB-dependent apoptosis [26].
The physical association between AhRR, ARNT and RelB was analyzed in co-immunoprecipitation
(co-IP) studies. Results indicate the interaction of AhRR not only with ARNT but also with RelB
in absence or presence of an AhR ligand (Figure 6B). TCDD did not affect the apparent association
between AhRR, ARNT, and RelB.
2.6. Inhibition of TCDD-Induced Apoptotic Resistance by AhRR
Apoptosis is a programmed cell death to eliminate dysfunctional or damaged cells. The ability
to escape apoptosis is an important characteristic of malignant cells and the development of cancer.
Therefore, we tested how AhRR affects the apoptotic response. A standard UV-induced apoptosis
test using the Annexin V-FITC Apoptosis Detection Kit (Sigma) was applied as described [4,27]. MEF
isolated from wt and AhRR Tg mice were used to examine the enhanced expression of AhRR on
TCDD-mediated apoptotic resistance. The exposure to UV light induced apoptosis in wt and AhRR Tg
MEF (Figure 7). MEF derived from wt mice showed that activation of AhR by TCDD has a significant
inhibitory effect on UV-induced apoptosis. AhRR overexpression inhibited TCDD-mediated apoptotic
resistance (Figure 7A). Furthermore, our results show that inhibition of PKA and CREB (required for
activity of C/EBPβ) as well as C/EBP DNA binding hinders TCDD’s anti-apoptotic response in MEF wt
(Figure 7B).
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3. Discussion
The results of the current study show that transgenic mice overexpressing AhRR inhibited
EL4 lymphoma growth in presence or absence of the exogenous AhR ligand TCDD. Furthermore,
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inflammatory conditions induced by LPS stimulated tumor growth of EL4 lymphoma cells in wt
mice, which was also suppressed in AhRR Tg mice indicating that AhRR may suppress tumor growth
independent of exogenous and toxic AhR ligands. Interestingly, the AhR has been shown to act as a
critical receptor protein that mediates tumor development independent of exogenous ligands [7]. The
authors concluded that the continuing activation of AhR via endogenous ligands such as kynurenine
represent a critical event in tumor promotion resulting in increased survival of cancer cells. Thus the
TCDD-independent yet AhRR-mediated tumor suppression is an important aspect, which may depend
on endogenous ligands produced by the tumor microenvironment or tumor cells directly.
Recently we reported that the most consistently observed trend found in TCDD-treated AhRR
Tg mice is an overall reduction in the responsiveness of several inflammation markers, especially
IL-1β and COX-2 [15]. The current study confirmed the repressed induction of IL-1β and COX-2 in
MEF and BMM overexpressing AhRR. Both inflammatory genes, COX-2 and IL-1β play a critical
role in carcinogenesis. We have previously shown, that C/EBPβ and COX-2 are important mediators
of an AhR-dependent and TCDD-induced resistance to an apoptotic response in lymphoma cells
demonstrating the critical role of COX-2 in the pathogenesis of lymphoma [4]. A previous report and
own data underlined the importance of C/EBPβ and COX-2 in the pathogenesis of lymphoma [28,29].
COX-2 is an inducible isoform upregulated in many cancers [30] and selective inhibition of COX-2 has
been shown to significantly increase apoptosis in tumors [31]. Degner et al. [32] have shown that AhR
ligands can upregulate COX-2 expression, which led to a pro-inflammatory local environment that
supported tumor development.
Furthermore, our results suggest that IL-1R signaling is an important mediator of TCDD-stimulated
growth of EL4 lymphoma cells in vivo. An interesting study using “triple-null” mice lacking IL-1
and TNFα receptors was performed in Chris Bradfield’s laboratory and demonstrated the important
role of IL-1β mediating TCDD’s toxic effects such as liver inflammation and tumor promoting
effects [33,34]. Early processes of carcinogenesis have been shown to be promoted via IL-1β signaling
and the pro-inflammatory microenvironment [35]. Furthermore, dysregulated levels of inflammatory
mediators are likely to play a key role in carcinogenesis mediated via environmental exposure as
recently reviewed [36]. The critical role of IL-1β was also demonstrated in inflammation-driven
carcinogenesis models using IL-1β-deficient mice treated with the procarcinogen and AhR ligand
3-methylcholanthrene (3-MC) [37]. Furthermore, transgenic mice that overexpress IL-1β developed
gastric inflammation and gastric cancer [38], a response also found in transgenic mice expressing a
constitutively active AhR [39]. Noticeably, we observed suppressed expression of COX-2 and IL-1β
associated with a reduced nuclear accumulation of C/EBPβ in AhRR Tg mice [15] and AhRR Tg MEF.
AhRR inhibits TCDD-mediated activation of PKA, which has been shown to induce DNA binding
activity of C/EBPβ [21]. Besides putative AhR binding sites, DNA binding elements for C/EBPβ
contribute to transcriptional activation of IL-1β and COX-2 [40,41]. We previously demonstrated that
PKA-mediated activation of C/EBPβ is a key transactivator for AhR-mediated Cox-2 gene induction [20].
Interestingly, studies have shown that PKA is critically involved in ligand independent activation of AhR
and the non-canonical AhR signaling pathway [24,42]. The current results show that TCDD-induced
IL-1β expression is also repressed when PKA and DNA binding of C/EBP are blocked. Furthermore,
we identified a RelB/AhR binding element on the promoter of IL-1β and found RelB to be important
mediating the expression of IL-1β confirming a previous study in dendritic cells [43]. Additionally,
we found that AhRR represses the induction of IL-1β and COX-2 in macrophages after stimulation
with LPS. Furthermore, AhRR Tg mice were protected from LPS shock as well as LPS-induced tumor
growth, which presents another important tumor suppressing function of AhRR since inflammatory
processes are major contributing factors promoting cancer development [44].
Activation of cAMP-dependent PKA as part of the non-canonical AhR pathway, leads to protein
phosphorylation including the cAMP response element binding protein (CREB), which regulates
activity of C/EBPβ [45]. C/EBPβ has been found to be an important factor in the autocrine survival
pathway of myeloid tumor cells [46]. Hyperproliferation and transformation of the normal mammary
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epithelial cells such as MCF10A cells has been found to be mediated by increased expression of
C/EBPβ [47]. On the other hand, deficiency of C/EBPβ led to an increased (17-fold) apoptosis of
epidermal keratinocytes in mice after treatment with a carcinogen. Furthermore, C/EBPβ null mice
were completely resistant to carcinogen-induced skin tumorigenesis and seem to be protected against
lymphomas in a carcinogenesis model compared to wt mice [48]. Inhibition of C/EBPβ in transgenic
mice caused regression of papillomas with an associated increase in apoptosis [49]. Previously we
have shown that TCDD inhibits UV-induced apoptosis in lymphoma cells, which requires functional
expression of COX-2 and C/EBPβ [4]. Furthermore, current data show that TCDD’s anti-apoptotic cell
response is significantly reduced in MEF from AhRR Tg mice, which requires PKA and C/EBP binding
and which is completely abrogated in MEF RelB−/−. The results confirm data with ectopic expression
of AhRR in human breast cancer cells [50] and previous reports showing that AhRR can act as a tumor
suppressor against several types of cancers [16,17].
4. Materials and Methods
4.1. Reagents and Antibodies
Dimethyl sulfoxide (DMSO) was purchased from Sigma. [γ-32P]ATP (6000 Ci/mmol) was provided
by ICN Biochemicals, Inc. (Costa Mesa, CA, USA). LPS isolated from Escherichia coli strain 055:B5 was
purchased from (Sigma Aldrich, St. Louis, MO, USA). TCDD (>99% purity) was originally obtained
from Dow Chemical Co. (Midland, MI, USA). Other molecular biological reagents were purchased from
Cayman Chemicals (Ann Arbor, MI, USA) and Applied Biosystems (Foster City, CA, USA). AhRR Tg
mice were genotype using the DNA/RNA Shield reagent (Zymo Research, Irvine, CA, USA) for nucleic
acids isolation. The antibodies against actin (sc-1616), C/EBPβ (sc-150), IL-1β (sc-7884), and ARNT
(sc-17811) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The purified rabbit
anti-AhRR antibody was purchased from Novoprotein (Summit, NJ, USA), COX-2-specific polyclonal
antibody and FICZ from Cayman Chemicals, AhR-specific polyclonal antibody from Enzo Life Sciences
(Farmingdale, NY, USA) and RelB-specific polyclonal antibody from Active Motif (Carlsbad, CA, USA).
4.2. Cell Culture and Transfection Experiments
MEF were isolated from wild type and AhRR Tg B6 mouse embryos and were cultured in
DMEM:F12 culture medium as described [51]. MEF were transiently transfected using jetPEI
(PolyTransfection; Qbiogene, Irvine, CA, USA), according to the manufacturer's instructions. The
transfection was allowed to proceed for 16 h, and cells were treated with 1 nM TCDD or 0.1%
DMSO (control) for 24 h before UV-irradiation. The luciferase reporter construct containing the IL-1β
promoter sequence was provided by SwitchGear Genomics (Menlo Park, CA, USA) corresponding to a
−2590 bp of the mouse promoter sequence. The protein kinase A inhibitor expression vector (PKA-i)
was kindly provided by Albert Smolenski (UCD Conway, Dublin, Ireland) and has been shown to
reduce cAMP-dependent protein kinase activity, but not protein kinase C activity. The A-CREB and
A-C/EBP vectors were kindly provided by Charles Vinson (NCI, Bethesda, MD, USA) and produce
dominant-negative proteins that specifically inhibit CREB phosphorylation and the DNA binding of
the C/EBP members, respectively.
4.3. Mice and Treatment
Female and male C57BL/6J wild type (wt) and AhRR Tg mice were housed in a selective
pathogen-free facility at UC Davis. Mice were maintained on a 12:12 h light/dark cycle and had free
access to water and food according to the guidelines set by the University of California. The protocol
for animal care and use was approved and completed by the Institutional Animal Care and Use
Committee (IACUC) on 10 December 2018 at the University of California Davis (#19671). This project
was conducted in accordance with the ILAR guide for the care and use of laboratory animals, and
the UC Davis Animal Welfare Assurance on file with the US Public Health Service. TCDD and LPS
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was administered via intraperitoneal (i.p.) injection for RNA, protein expression analysis, and LPS
shock experiments. To address the tumor-suppressive action of AhRR in vivo, we used a syngeneic
murine tumor model to evaluate in tumor susceptibility in wt and AhRR Tg mice. To create tumors, we
used an orthotopic xenograft tumor model by subcutaneous (s.c.) injection of EL4 mouse lymphoma
cells. The EL4 mouse lymphoma cells were established from a lymphoma induced in a B6 mouse by
9,10-dimethyl-1,2-benzanthracene [52]. The cultured EL4 tumor cell suspension was resuspended in
PBS to obtain the desired EL4 tumor cell concentration of 500,000 cells/mL. A 1 mL syringe affixed
with a 23-G needle was loaded with 0.1 mL of the EL4 tumor cell suspension (50,000 cells). For control,
100 mL PBS alone was injected. EL4 cells were injected subcutaneously into the right rear thigh of
wt and AhRR Tg mice (10 weeks old, female and male with six animals in each group). 24 h after
injection of EL4 cells, mice were treated with vehicle (corn oil or PBS) and TCDD (10 µg/kg bw) or LPS
(2.5 mg/kg bw) in order to test possible enhancing effects of TCDD and the inflammatory stimulus LPS
on tumor growth of EL4 lymphoma cells in wt and AhRR Tg mice. To block the effect of increased IL-1β
production the IL-1 receptor antagonist anakinra was administered at 30 mg/kg. The COX-2 selective
inhibitor NS-398 was administered at a dose of 36 mg/kg bw. Anakinra and NS-398 were administered
i.p. 30 min before injection of TCDD. As a maintenance dose the inhibitors were administered at
the original dose every 4 days according to its half-life in vivo. Doses and timing of anakinra and
NS-398 were chosen based on their effectiveness in preventing disease endpoints in vivo [53,54]. Each
mouse was palpated daily at the injection site and the tumor size was measured daily using a slide
microcaliper for 24 days post-injection. These data were used to determine the tumor volume by
employing the following formula V = (L×W×H)/2.
4.4. Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts were isolated from MEF as described previously [24]. Cells were treated with LPS
or TCDD for 90 min and harvested in ice cold Dulbecco’s PBS. The DNA/protein binding reactions were
carried out in a total volume of 15 µL containing 10 µg of nuclear protein, 60,000 cpm of double-stranded
C/EBP consensus oligonucleotide (5′-TGCAGATTGCGCAATCTGCA-3′) plus 1 µg of poly(dI·dC). The
samples were incubated at room temperature for 20 min. Competition experiments were performed in
the presence of a 100-fold molar excess of unlabeled oligo. Protein-DNA complexes were resolved
on a nondenaturating polyacrylamide gel and visualized by exposure of the dried gels to x-ray films.
Protein-DNA complexes were quantified using a ChemiImagerTM 4400 (Alpha Innotech Corp., San
Leandro, CA, USA).
4.5. RNA Isolation and Real-Time PCR
Total RNA was isolated from cells using a Quick-RNA Mini prep isolation kit (Zymo Research),
and cDNA synthesis was performed as described [4] using a cDNA synthesis kit Applied Biosystems
(Foster City, CA, USA). Detection of β-actin and differentially expressed target genes was performed
with a LightCycler LC480 Instrument (Roche Diagnostics, Indianapolis, IN, USA) using the Fast SYBR
Green Master Mix (Applied Biosystems) according to the manufacturer's instructions. The primers for
each gene were designed on the basis of the respective cDNA or mRNA sequences using OLIGO primer
analysis software provided by Steve Rozen and the Whitehead Institute/Massachusetts Institute of
Technology Center for Genome Research so that the targets were 100–200 bp in length. PCR amplification
was carried as described [4]. To confirm the amplification specificity, the PCR products were subjected
to melting curve analysis.
4.6. Protein Kinase A (PKA) Assays
PKA activity was determined in cell lysates using a PKA assay kit (Upstate Biotechnology Inc.,
Lake Placid, NY, USA) as described previously [21]. Briefly, the total PKA activity was measured by the
addition of 2 µM cAMP; basal activity, a measure of active PKA at the time of harvest, was measured
in the absence of exogenous cAMP. The amount of 32P was quantified by scintillation counting.
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Nonspecific activity was subtracted by using a PKA inhibitor peptide. To examine AhR-dependent
effects, TCDD-treated cells were simultaneously treated with the AhR antagonists MNF (5 µM) or
CH223191 (10 µM).
4.7. ChIP Assay
MEF cells were treated with TCDD for the indicated times and protein-DNA complexes were
cross-linked with 1% formaldehyde for 10 min and prepared for ChIP assay as described [24].
DNA was purified using a DNA purification kit (Zymo Research) and eluted in 50 µL. ChIP DNA
(5 µL) was amplified by real-time PCR with primers 5′-ATCCAGTTACCAAACTCCAAC-3′ and
5′-ATTGACACCATCTGCACAATT-3′ covering the specified region RelBAhRE of IL-1β to amplify a
188 bp fragment of the IL-1β promoter.
4.8. Nuclear Complex Co-Immunoprecipitation Assay
Preparation of nuclear extracts and co-immunoprecipitation was performed as described [21].
To analyze level of AhR and RelB protein in nuclei, nuclear protein extracts (15 µg) were separated on
a 10% SDS-polyacrylamide gel and blotted onto a PVDF membrane (Immuno-Blot, BioRad, Hercules,
CA, USA). The antigen-antibody complexes were visualized using the chemoluminescence substrate
SuperSignal®, West Pico (Pierce, Rockford, IL, USA).
4.9. Western Blot Analysis
Whole cell lysates were prepared on ice with RIPA buffer containing protease inhibitor cocktail
(Roche) as described [21]. The lysates were centrifuged at 16,000× g at 4 ◦C for 10 min, and the supernatants
were collected as whole cell lysates. Whole cell lysates were separated on a SDS-polyacrylamide gel
and blotted onto a PVDF membrane (Immuno-Blot, Bio-Rad). The antigen-antibody complexes were
visualized using the chemiluminescence substrate SuperSignal®, West Pico (Pierce). For quantitative
analysis, respective bands were quantified using a ChemilmagerTM 4400 (Alpha Innotech Corporation,
San Leandro, CA, USA).
4.10. Apoptosis Assay on UV-Irradiated Cells
MEF cells (5 × 105 cells) were seeded in a 6 cm dish and exposed to TCDD for 24 h prior to
UV-irradiation and apoptosis was detected by Annexin V staining as described previously [4].
4.11. Statistical Analysis
All experiments were repeated a minimum of three times, and data are expressed as mean ± S.D.
Differences were considered significant at p < 0.05. A comparison of two groups was made with an
unpaired, two-tailed Student’s t test. A comparison of multiple groups was made with analysis of
variance followed by a Dunnett’s or Tukey’s test.
5. Conclusions
In summary, our data indicate that the tumor suppressive function of AhRR is mediated via its
interaction with the non-canonical AhR pathway (Figure 8) resulting in down-regulation of cellular
inflammation through inhibition of the PKA-C/EBPβ inflammatory axis and inhibition of tumor growth
and lymphoma.
Cancers 2019, 11, 589 14 of 17
Cancers 2019, 11, x 13 of 17 
 
4.8. Nuclear Complex Co-Immunoprecipitation Assay 
Preparation of nuclear extracts and co-immunoprecipitation was performed as described [21]. 
To analyze level of AhR and RelB protein in nuclei, nuclear protein extracts (15 μg) were separated 
on a 10% SDS-polyacrylamide gel and blotted onto a PVDF membrane (Immuno-Blot, BioRad, 
Hercules, CA, USA). The antigen-antibody complexes were visualized using the chemoluminescence 
substrate SuperSignal® , West Pico (Pierce, Rockford, IL, USA). 
4.9. Western Blot Analysis 
Whole cell lysates were prepared on ice with RIPA buffer containing protease inhibitor cocktail 
(Roche) as described [21]. The lysates were centrifuged at 16,000× g at 4 °C for 10 min, and the 
supernatants were collected as whole cell lysates. Whole cell lysates were separated on a SDS-
polyacrylamide gel and blotted onto a PVDF membrane (Immuno-Blot, Bio-Rad). The antigen-
antibody complexes were visualized using the chemiluminescence substrate SuperSignal® , West Pico 
(Pierce). For quantitative analysis, respective bands were quantified using a ChemilmagerTM 4400 
(Alpha Innotech Corporation, San Leandro, CA, USA). 
4.10. Apoptosis Assay on UV-Irradiated Cells 
MEF cells (5 × 105 cells) were seeded in a 6 cm dish and exposed to TCDD for 24 h prior to UV-
irradiation and apoptosis was detected by Annexin V staining as described previously [4]. 
4.11. Statistical Analysis 
All experiments were repeated a minimum of three times, and data are expressed as mean ± S.D. 
Differences were considered significant at p < 0.05. A comparison of two groups was made with an 
unpaired, two-tailed Student’s t test. A comparison of multiple groups was made with analysis of 
variance followed by a Dunnett’s or Tukey’s test. 
5. Conclusions 
In summary, our data indicate that the tumor suppressive function of AhRR is mediated via its 
interaction with the non-canonical AhR pathway (Figure 8) resulting in down-regulation of cellular 
inflammation through inhibition of the PKA-C/EBPβ inflammatory axis and inhibition of tumor 
growth and lymphoma. 
 
Figure 8. A schematic diagram illustrates our hypothesis how AhRR may interact with the canonical 
and non-canonical AhR signaling pathways as described recently [11]. AhRR may suppress 
AhR
AhR
ARNT AhRR ARNT
RelB
canonical AhR pathway non-canonical AhR pathway
PKA activation
AhR gene battery,
i.e. CYP1 enzyme activity
Pro-Inflammatory response 
(C/EBPb, IL-1b, COX-2)
Tumor promotion,
Lymphoma 
. sche atic diagram illustrates our hypothesis how AhRR may interact with the canonical and
non-canonical AhR signaling p thways as described r cently [11]. AhRR may suppress inflammatory
responses and tumor promotion via interaction with RelB in complex with AhR and ARNT. Double
arrows depict the interaction of AhRR with ARNT and RelB with AhR.
Author Contributions: Project was planned by C.F.A.V. Plasmids, cell lines, and critical resources were provided
by J.M.T., C.S., T.H.-S., and Y.I., C.F.A.V., S.Y.K., C.E.C., A.N.-C., Y.I., C.S. and M.P. performed the majority of the
experiments and interpreted the data. Statistical analyses were performed by S.Y.K. and C.F.A.V. Original draft
preparation was done by C.F.A.V., T.H.-S. and J.M.T. All authors reviewed the manuscript.
Funding: Research reported in this publication is supported in part by the National Institute of Environmental
Health Sciences of the National Institutes of Health under Award Number R01 ES029126 and R21 ES030419,
the core center grant, P30-ES023513 from the National Institute of Environmental Health Sciences, and by the
University of California Davis Cancer Center support grant P30 CA093373 and the Cancer Immunology Grant
fund 48649. Its contents are solely the responsibility of the authors and do not necessarily represent the official
views of the National Institutes of Health.
Acknowledgments: We like to thank Sasha Wirth from the Mouse Biology Program at UC Davis for technical
assistance to generate transgenic AhRR mice. We like to thank Charles Vinson and Albert Smolenski for providing
critical plasmid constructs and Alexander Hoffmann for providing RelB deficient MEF.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Van den Berg, M.; Denison, M.S.; Birnbaum, L.S.; Devito, M.J.; Fiedler, H.; Falandysz, J.; Rose, M.; Schrenk, D.;
Safe, S.; Tohyama, C.; et al. Polybrominated dibenzo-p-dioxins, dibenzofurans, and biphenyls: Inclusion in
the toxicity equivalency factor concept for dioxin-like compounds. Toxicol. Sci. 2013, 133, 197–208. [CrossRef]
2. Pitot, H.C.; Goldsworthy, T.; Campbell, H.A.; Poland, A. Quantitative evaluation of the promotion by
2,3,7,8-tetrachlorodibenzo-p-dioxin of hepatocarcinogenesis from diethylnitrosamine. Cancer Res. 1980, 40,
3616–3620. [PubMed]
3. Castro, D.J.; Löhr, C.V.; Fischer, K.A.; Pereira, C.B.; Williams, D.E. Lymphoma and lung cancer in offspring
born to pregnant mice dosed with dibenzo[a,l]pyrene: The importance of in utero vs. lactational exposure.
Toxicol. Appl. Pharmacol. 2008, 233, 454–468. [CrossRef]
4. Vogel, C.F.; Li, W.; Sciullo, E.; Newman, J.; Hammock, B.; Reader, J.R.; Tuscano, J.; Matsumura, F.
Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased
cyclooxygenase-2 expression. Am. J. Pathol. 2007, 171, 1538–1548. [CrossRef]
5. Landgren, O.; Shim, Y.K.; Michalek, J.; Costello, R.; Burton, D.; Ketchum, N.; Calvo, K.R.; Caporaso, N.;
Raveche, E.; Middleton, D.; et al. Agent orange exposure and monoclonal gammopathy of undetermined
significance: An operation ranch hand veteran cohort study. JAMA Oncol. 2015, 1, 1061–1068.
Cancers 2019, 11, 589 15 of 17
6. Xu, J.; Ye, Y.; Huang, F.; Chen, H.; Wu, H.; Huang, J.; Hu, J.; Xia, D.; Wu, Y. Association between dioxin and
cancer incidence and mortality: A meta-analysis. Sci. Rep. 2016, 6, 38012. [CrossRef]
7. Opitz, C.A.; Litzenburger, U.M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.;
Schrenk, D.; Weller, M.; et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon
receptor. Nature 2011, 478, 197–203. [CrossRef]
8. Dragan, Y.P.; Schrenk, D. Animal studies addressing the carcinogenicity of TCDD (or related compounds)
with an emphasis on tumour promotion. Food Addit. Contam. 2000, 4, 289–302. [CrossRef] [PubMed]
9. Mimura, J.; Ema, M.; Sogawa, K.; Fujii-Kuriyama, Y. Identification of a novel mechanism of regulation of Ah
(dioxin) receptor function. Genes Dev. 1999, 13, 20–25. [CrossRef] [PubMed]
10. Hahn, M.E.; Allan, L.L.; Sherr, D.H. Regulation of constitutive and inducible AHR signaling: Complex
interactions involving the AHR repressor. Biochem. Pharmacol. 2009, 77, 485–497. [CrossRef] [PubMed]
11. Vogel, C.F.; Haarmann-Stemmann, T. The aryl hydrocarbon receptor repressor—More than a simple feedback
inhibitor of AhR signaling: Clues for its role in inflammation and cancer. Curr. Opin. Toxicol. 2017, 2, 109–119.
[CrossRef] [PubMed]
12. Tigges, J.; Weighardt, H.; Wolff, S.; Götz, C.; Förster, I.; Kohne, Z.; Huebenthal, U.; Merk, H.F.; Abel, J.;
Haarmann-Stemmann, T.; et al. Aryl hydrocarbon receptor repressor (AhRR) function revisited: Repression
of CYP1 activity in human skin fibroblasts is not related to AhRR expression. J. Invest. Dermatol. 2013, 133,
87–96. [CrossRef] [PubMed]
13. Sakurai, S.; Shimizu, T.; Ohto, U. The crystal structure of the AhRR/ARNT heterodimer reveals the structural
basis of the repression of AhR-mediated transcription. J. Biol. Chem. 2017, 292, 17609–17616. [CrossRef]
[PubMed]
14. Evans, B.R.; Karchner, S.I.; Allan, L.L.; Pollenz, R.S.; Tanguay, R.L.; Jenny, M.J.; Sherr, D.H.; Hahn, M.E.
Repression of aryl hydrocarbon receptor (AHR) signaling by AHR repressor: Role of DNA binding and
competition for AHR nuclear translocator. Mol. Pharmacol. 2008, 73, 387–398. [CrossRef] [PubMed]
15. Vogel, C.F.; Chang, W.L.; Kado, S.; McCulloh, K.; Vogel, H.; Wu, D.; Haarmann-Stemmann, T.; Yang, G.;
Leung, P.S.; Matsumura, F.; et al. Transgenic overexpression of aryl hydrocarbon receptor repressor (AhRR)
and AhR-mediated induction of CYP1A1, cytokines, and acute toxicity. Environ. Health Perspect. 2016, 124,
1071–1083. [CrossRef]
16. Zudaire, E.; Cuesta, N.; Murty, V.; Woodson, K.; Adams, L.; Gonzalez, N.; Martínez, A.; Narayan, G.; Kirsch, I.;
Franklin, W.; et al. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple
human cancers. J. Clin. Invest. 2008, 118, 640–650. [CrossRef] [PubMed]
17. Schlezinger, J.J.; Liu, D.; Farago, M.; Seldin, D.C.; Belguise, K.; Sonenshein, G.E.; Sherr, D.H. A role for the
aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol. Chem. 2006, 387, 1175–1187. [CrossRef]
18. Yang, S.Y.; Ahmed, S.; Satheesh, S.V.; Matthews, J. Genome-wide mapping and analysis of aryl hydrocarbon
receptor (AHR)- and aryl hydrocarbon receptor repressor (AHRR)-binding sites in human breast cancer cells.
Arch. Toxicol. 2018, 1, 225–240. [CrossRef] [PubMed]
19. Lee, K.W.; Richmond, R.; Hu, P.; French, L.; Shin, J.; Bourdon, C. Prenatal exposure to maternal cigarette
smoking and DNA methylation: Epigenome-wide association in a discovery sample of adolescents and
replication in an independent cohort at birth through 17 years of age. Environ. Health Perspect. 2015, 123,
193–199. [CrossRef]
20. Vogel, C.; Boerboom, A.M.; Baechle, C.; El-Bahay, C.; Kahl, R.; Degen, G.H.; Abel, J. Regulation of
prostaglandin endoperoxide H synthase-2 induction by dioxin in rat hepatocytes: Possible c-Src-mediated
pathway. Carcinogenesis 2000, 21, 2267–2274. [CrossRef]
21. Vogel, C.F.; Sciullo, E.; Park, S.; Liedtke, C.; Trautwein, C.; Matsumura, F. Dioxin increases C/EBPbeta
transcription by activating cAMP/protein kinase A. J. Biol. Chem. 2004, 279, 8886–8894. [CrossRef]
22. Sutter, T.R.; Guzman, K.; Dold, K.M.; Greenlee, W.F. Targets for dioxin: Genes for plasminogen activator
inhibitor-2 and interleukin-1 beta. Science 1991, 254, 415–418. [CrossRef]
23. Brandstätter, O.; Schanz, O.; Vorac, J.; König, J.; Mori, T.; Maruyama, T.; Korkowski, M.; Haarmann-Stemmann, T.;
von Smolinski, D.; Schultze, J.L.; et al. Balancing intestinal and systemic inflammation through cell type-specific
expression of the aryl hydrocarbon receptor repressor. Sci. Rep. 2016, 17, 26091. [CrossRef]
24. Vogel, C.F.; Sciullo, E.; Li, W.; Wong, P.; Lazennec, G.; Matsumura, F. RelB, a new partner of aryl hydrocarbon
receptor-mediated transcription. Mol. Endocrinol. 2007, 12, 2941–2955. [CrossRef] [PubMed]
Cancers 2019, 11, 589 16 of 17
25. Wright, C.W.; Duckett, C.S. The aryl hydrocarbon nuclear translocator alters CD30-mediated
NF-kappaB-dependent transcription. Science 2009, 323, 251–255. [CrossRef] [PubMed]
26. Gardella, K.A.; Muro, I.; Fang, G.; Sarkar, K.; Mendez, O.; Wright, C.W. Aryl hydrocarbon receptor nuclear
translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating
tumor suppressor p53 activity. Oncotarget 2016, 7, 10710–10722. [CrossRef]
27. Vogel, C.F.; Li, W.; Wu, D.; Miller, J.K.; Sweeney, C.; Lazennec, G.; Fujisawa, Y.; Matsumura, F. Interaction
of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8
overexpression. Arch. Biochem. Biophys. 2011, 512, 78–86. [CrossRef]
28. Secchiero, P.; Barbarotto, E.; Gonelli, A.; Tiribelli, M.; Zerbinati, C.; Celeghini, C.; Agostinelli, C.; Pileri, S.A.;
Zauli, G. Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid
leukemia cells. Am. J. Pathol. 2005, 167, 1599–1607. [CrossRef]
29. Wun, T.; McKnight, H.; Tuscano, J.M. Increased cyclooxygenase-2 (COX-2): A potential role in the pathogenesis
of lymphoma. Leuk. Res. 2004, 28, 179–190. [CrossRef]
30. Wang, D.; Dubois, R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10, 181–193. [CrossRef]
31. Buchanan, F.G.; Holla, V.; Katkuri, S.; Matta, P.; DuBois, R.N. Targeting cyclooxygenase-2 and the epidermal
growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 2007, 67, 9380–9388.
[CrossRef] [PubMed]
32. Degner, S.C.; Papoutsis, A.J.; Selmin, O.; Romagnolo, D.F. Targeting of aryl hydrocarbon receptor-mediated
activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast
cancer cells. J. Nutr. 2009, 139, 26–32. [CrossRef] [PubMed]
33. Pande, K.; Moran, S.M.; Bradfield, C.A. Aspects of dioxin toxicity are mediated by interleukin 1-like cytokines.
Mol. Pharmacol. 2005, 67, 1393–1398. [CrossRef] [PubMed]
34. Kennedy, G.D.; Nukaya, M.; Moran, S.M.; Glover, E.; Weinberg, S.; Balbo, S.; Hecht, S.S.; Pitot, H.C.;
Drinkwater, N.R.; Bradfield, C.A. Liver tumor promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin is dependent
on the aryl hydrocarbon receptor and TNF/IL-1 receptors. Toxicol. Sci. 2014, 140, 135–143. [CrossRef] [PubMed]
35. Jain, A.; Kaczanowska, S.; Davila, E. Il-1 receptor-associated kinase signaling and its role in inflammation,
cancer progression, and therapy resistance. Front Immunol. 2014, 5, 553. [CrossRef] [PubMed]
36. Thompson, P.A.; Khatami, M.; Baglole, C.J.; Sun, J.; Harris, S.; Moon, E.Y. Environmental immune disruptors,
inflammation and cancer risk. Carcinogenesis 2015, 36, 232–253. [CrossRef]
37. Krelin, Y.; Voronov, E.; Dotan, S.; Elkabets, M.; Reich, E.; Fogel, M.; Huszar, M.; Iwakura, Y.; Segal, S.;
Dinarello, C.A.; et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of
chemical carcinogen-induced tumors. Cancer Res. 2007, 67, 1062–1071. [CrossRef]
38. Tu, S.; Bhagat, G.; Cui, G.; Takaishi, S.; Kurt-Jones, E.A.; Rickman, B.; Betz, K.S.; Penz-Oesterreicher, M.;
Bjorkdahl, O.; Fox, J.G.; et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer
and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14, 408–419. [CrossRef]
39. Andersson, P.; McGuire, J.; Rubio, C.; Gradin, K.; Whitelaw, M.L.; Pettersson, S.; Hanberg, A.; Poellinger, L.
A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl. Acad. Sci. USA
2002, 99, 9990–9995. [CrossRef]
40. Basak, C.; Pathak, S.K.; Bhattacharyya, A.; Mandal, D.; Pathak, S.; Kundu, M. NF-kappaB- and
C/EBPbeta-driven interleukin-1beta gene expression and pak1-mediated caspase-1 activation play essential
roles in interleukin-1beta release from helicobacter pylori lipopolysaccharide-stimulated macrophages. J. Biol.
Chem. 2005, 280, 4279–4288. [CrossRef]
41. Fletcher, B.S.; Kujubu, D.A.; Perrin, D.M.; Herschman, H.R. Structure of the mitogen-inducible TIS10 gene
and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J. Biol. Chem.
1992, 267, 4338–4344.
42. Oesch-Bartlomowicz, B.; Huelster, A.; Wiss, O.; Antoniou-Lipfert, P.; Dietrich, C.; Arand, M.; Weiss, C.;
Bockamp, E.; Oesch, F. Aryl hydrocarbon receptor activation by cAMP vs. dioxin: Divergent signaling
pathways. Proc. Natl. Acad. Sci. USA 2005, 102, 9218–9223. [CrossRef] [PubMed]
43. Shih, V.F.; Davis-Turak, J.; Macal, M.; Huang, J.Q.; Ponomarenko, J.; Kearns, J.D.; Yu, T.; Fagerlund, R.;
Asagiri, M.; Zuniga, E.I.; et al. Control of RelB during dendritic cell activation integrates canonical and
noncanonical NF-κB pathways. Nat. Immunol. 2012, 13, 1162–1170. [CrossRef] [PubMed]
44. Coussens, L.M.; Zitvogel, L.; Palucka, A.K. Neutralizing tumor-promoting chronic inflammation: A magic
bullet? Science 2013, 339, 286–291. [CrossRef] [PubMed]
Cancers 2019, 11, 589 17 of 17
45. Niehof, M.; Streetz, K.; Rakemann, T.; Bischoff, S.C.; Manns, M.P.; Horn, F.; Trautwein, C. Interleukin-6-induced
tethering of STAT3 to the LAP/C/EBP beta promoter suggests a new mechanism of transcriptional regulation
by STAT3. J. Biol. Chem. 2001, 276, 9016–9027. [CrossRef] [PubMed]
46. Wessells, J.; Yakar, S.; Johnson, P.F. Critical prosurvival roles for C/EBP beta and insulin-like growth factor I
in macrophage tumor cells. Mol. Cell Biol. 2004, 24, 3238–3250. [CrossRef] [PubMed]
47. Bundy, L.M.; Sealy, L. CCAAT/enhancer binding protein beta (C/EBPbeta)-2 transforms normal mammary
epithelial cells and induces epithelial to mesenchymal transition in culture. Oncogene 2003, 22, 869–883.
[CrossRef]
48. Johnson, P.; National Cancer Institute, Frederick, MD, USA. Personal communication, 2008.
49. Oh, W.J.; Rishi, V.; Orosz, A.; Gerdes, M.J.; Vinson, C. Inhibition of CCAAT/enhancer binding protein family
DNA binding in mouse epidermis prevents and regresses papillomas. Cancer Res. 2007, 67, 1867–1876.
[CrossRef]
50. Wong, P.S.; Li, W.; Vogel, C.F.; Matsumura, F. Characterization of MCF mammary epithelial cells
overexpressing the Arylhydrocarbon receptor (AhR). BMC Cancer 2009, 9, 234. [CrossRef]
51. Vogel, C.F.; Matsumura, F. Interaction of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) with induced adipocyte
differentiation in mouse embryonic fibroblasts (MEFs) involves tyrosine kinase c-Src. Biochem. Pharmacol.
2003, 7, 1231–1244. [CrossRef]
52. Ng, S.; Yoshida, K.; Zelikoff, J.T. Tumor challenges in immunotoxicity testing. Methods Mol. Biol. 2010, 598,
143–155. [PubMed]
53. Selig, W.; Tocker, J. Effect of interleukin-1 receptor antagonist on antigen-induced pulmonary responses in
guinea pigs. Eur. J. Pharmacol. 1992, 213, 331–336. [CrossRef]
54. Pyo, H.; Choy, H.; Amorino, G.P.; Kim, J.S.; Cao, Q.; Hercules, S.K.; DuBois, R.N. A selective cyclooxygenase-2
inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express
cyclooxygenase-2. Clin. Cancer Res. 2001, 10, 2998–3005.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
